EN
Current Location:Home ProductsPipeline

Pipeline

  • Drug
  • Target
  • Indication
  • Phase
  • BLA
  • Cooperation
PreclinicalPhase IPhase IIPhase III
QX002N
TargetIL-17A
Indication
PhasePreclinicalPhase IPhase IIPhase III
AS
LN
view more
QX005N
TargetIL-4Rα
Indication
PhasePreclinicalPhase IPhase IIPhase III
moderate-to-severeAD
PN
CRSwNP
CSU
moderate-to-severe asthma
COPD
adolescent AD
view more
QX001S
TargetIL-12/IL-23p40
Indication
PhasePreclinicalPhase IPhase IIPhase III
moderate-to-severe plaque Ps
UC/CD
view more
QX004N
TargetIL-23p19
Indication
PhasePreclinicalPhase IPhase IIPhase III
Ps
CD
view more
QX006N
TargetIFNAR1
Indication
PhasePreclinicalPhase IPhase IIPhase III
SLE
view more
QX008N
TargetTSLP
Indication
PhasePreclinicalPhase IPhase IIPhase III
asthma
severe asthma
moderate-to-severe COPD
view more
QX007N
TargetIL-33
Indication
PhasePreclinicalPhase IPhase IIPhase III
COPD
view more
QX013N
Targetc-kit
Indication
PhasePreclinicalPhase IPhase IIPhase III
CSU
view more
QX010N
TargetIL-31R
Indication
PhasePreclinicalPhase IPhase IIPhase III
pruritus
view more

AD: atopic dermatitis

CRSwNP: chronic rhinosinusitis with nasal polyps

Ps: psoriasis

AS: ankylosing spondylitis

CSU: chronic spontaneous urticaria

SLE: systemic lupus erythematosus

CD: Crohn’s disease

LN: lupus nephritis

UC: ulcerative colitis

COPD: chronic obstructive pulmonary disease

PN: prurigo nodularis

IFNAR1: interferon-alpha/beta receptor subunit 1

IL-4Rα interleukin-4 receptor subunitα

IL-12/IL-23p40: interleukin-12/interleukin-23 subunit p40

IL-17A: interleukin-17A

IL-23p19: interleukin-23 subunit p19

IL-31R: interleukin-31 receptor

IL-33: interleukin-33

TSLP: thymic stromal lymphopoietin


​Pipeline updated to 2023-03-31

Clinical-stage Pipeline Products

  • Skin
  • Rheumatic
  • Respiratory
  • Digestive